<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ONDANSETRON HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(on-dan'si-tron)<br/><span class="topboxtradename">Zofran, </span><span class="topboxtradename">Zofran ODT<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span>; <span class="classification">5-ht<sub>3</sub> antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; 2 mg/mL, 32 mg/5 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Selective serotonin (5-HT<sub>3</sub>) receptor antagonist. Serotonin receptors are located centrally in the chemoreceptor trigger zone (CTZ) and peripherally
         on the vagal nerve terminals. Serotonin is released from the wall of the small intestine and stimulates the vagal efferents
         through the serotonin receptors and initiates the vomiting reflex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents nausea and vomiting associated with cancer chemotherapy and anesthesia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of nausea and vomiting associated with initial and repeated courses of cancer chemotherapy, including high-dose
         cisplatin; postoperative nausea and vomiting.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of hyperemesis gravidarum</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ondansetron.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 8 mg 30 min before chemotherapy, then q8h times 2 more doses<br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>6 mo18 y,</i> 0.15 mg/kg or 32 mg infused over 15 min beginning 30 min before start of chemotherapy, followed by 0.15 mg/kg 4 and 8 h after
               first dose of ondansetron, may also give 8 mg bolus, then 1 mg/h by continuous infusion (max: 32 mg/d), or 32 mg as single
               dose<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;4 y,</i> 4 mg 30 min before chemotherapy, then q8h times 2 more doses<br/><br/><span class="indicationtitle">Nausea &amp; Vomiting with Highly Emetogenic Chemotherapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Single 24-mg dose 30 min before administration of single-day highly emetogenic chemotherapy<br/><br/><span class="indicationtitle">Postoperative Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 816 mg 1 h preoperatively <span class="rdroute">IM</span> 4 mg injected immediately prior to anesthesia induction or once postoperatively if patient experiences nausea/vomiting shortly
               after surgery <span class="rdroute">IV</span> 4 mg by slow IV push, may repeat q8h as needed<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>1 mo12</i>
<i>y,</i> 0.1 mg/kg<br/><br/><span class="indicationtitle">Hyperemesis Gravidarum</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 48 mg 23 times per day<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Maximum dose 8 mg/d PO/IV in patients with severely impaired liver function according to Child-Pugh criteria<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give tablets 30 min prior to chemotherapy and 12 h prior to radiation therapy.</li>
<li>Do <small>NOT</small> push orally disintegrating tablet through blister foil. Peel foil back and remove tablet. Tablets will disintegrate with/without
            liquid.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted.  <span class="methodtype">IV Infusion:</span>  Dilute a single does in 50 mL of D5W or NS. May be further diluted in selected IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over at least 30 sec, 25 min preferred.  <span class="methodtype">IV Infusion:</span>  Give over 15 min. When three separate doses are administered, infuse each over 15 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Meropenem.</b>
<span class="incompattype"> Y-site:</span>
<b>Acyclovir,</b>
<b>allopurinol,</b>
<b>aminophylline,</b>
<b>amphotericin B,</b>
<b>ampicillin,</b>
<b>ampicillin/sulbactam,</b>
<b>amsacrine,</b>
<b>cefepime,</b>
<b>cefoperazone,</b>
<b>fluorouracil,</b>
<b>furosemide,</b>
<b>ganciclovir,</b>
<b>lorazepam,</b>
<b>meropenem,</b>
<b>methylprednisolone,</b>
<b>piperacillin,</b>
<b>sargramostim,</b>
<b>sodium bicarbonate,</b>
<b>TPN.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness and light-headedness, <span class="speceff-common">headache, sedation</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span> constipation, dry mouth, transient increases in liver aminotransferases and bilirubin. <span class="typehead">Body as a Whole:</span> Hypersensitivity reactions. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Rifampin</b> may decrease ondansetron levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 11.5 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 4460% excreted in urine within 24 h; approximately 25% excreted in feces. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor fluid and electrolyte status. Diarrhea, which may cause fluid and electrolyte imbalance, is a potential adverse effect
            of the drug.
         </li>
<li>Monitor cardiovascular status, especially in patients with a history of coronary artery disease. Rare cases of tachycardia
            and angina have been reported.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that headache requiring an analgesic for relief is a common adverse effect.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>